Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Jul 15, 2017; 9(7): 281-292
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.281
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.281
Table 1 Summary of adjuvant studies for early stage pancreatic cancer
| Adjuvant systemic therapy | |||||||||
| Study[20,22-24,26,27,29] | Treatment | Treatment group | Control group | ||||||
| DFS (mo) | OS (mo) | 2 yr survival | 5 yr survival | DFS (mo) | OS (mo) | 2 yr survival | 5 yr survival | ||
| 5-FU based treatments | |||||||||
| ESPAC-1 Neoptolemos et al[20], 2001 | 5-FU/LV vs observation | - | 19.7 | - | - | - | 14.0 | - | - |
| ESPAC-1 and 3 pooled analysis Neoptolemos et al[22], 2009 | 5-FU/LV vs observation | - | 23.2 | 49.0% | 24.0% | - | 16.8 | 37.0% | 14.0% |
| Gemcitabine based treatments | |||||||||
| CONKO-001, Oettle et al[24], 2007 | Gemcitabine vs observation | 13.4 | 22.1 | - | 16.5% | 6.9 | 20.5 | - | 5.5% |
| JSAP-02, Ueno et al[26], 2009 | Gemcitabine vs observation | 11.4 | 22.3 | 48.3% | 23.9% | 5.0 | 18.4 | 40.0% | 10.6% |
| Gemcitabine compared to 5-FU | |||||||||
| ESPAC-3, Neoptolemos et al[23], 2010 | Gemcitabine vs 5-FU/LV | 14.3 | 23.6 | 29.6% | - | 14.1 | 23.0 | 30.7% | - |
| RTOG 97-04, Regine et al[27], 2008 | Gemcitabine vs 5-FU/LV in patients receiving CRT | - | 20.5 | - | - | - | 16.9 | - | - |
| Combination treatments | |||||||||
| ESPAC-4, Neoptolemos et al[29], 2017 | Gemcitabine plus capecitabine vs Gemcitabine | 13.9 | 28.0 | 53.8% | - | 13.1 | 25.5 | 52.1% | - |
- Citation: Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292
- URL: https://www.wjgnet.com/1948-5204/full/v9/i7/281.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i7.281